随着寒潮持续南下，全国多地进入呼吸道与消化道传染病的叠加风险期。诺如病毒感染性腹泻进入季节 性高发，学校、家庭聚集性疫情频现，儿童因免疫系统尚未成熟，成为最易受侵袭的群体。专家提醒， 冬季防控需"胃肠同治"，家庭科学备药与及时干预尤为关键。 诺如病毒传播途径多样，可通过污染的食物、水、物品甚至气溶胶传播，传染性极强。患儿往往突发呕 吐、腹泻、发热，易引发脱水与电解质紊乱。儿科门诊数据显示，冬季因急性肠道炎就诊的儿童中，诺 如病毒感染占比显著升高。 不少家长误将儿童腹泻当作普通着凉，自行使用成人药物或抗生素，反而可能扰乱肠道菌群，延误病 情。专家强调，儿童肠道娇嫩，药物选择应遵循安全、对症、适口三大原则，避免不当用药造成二次伤 害。 儿童装康恩贝肠炎宁颗粒：多维卖点构筑儿童肠道健康防线 针对儿童肠道特点与用药需求，儿童装康恩贝肠炎宁颗粒凭借以下核心优势，成为众多家庭冬季常备的 安心之选： 肠道被称为"第二大脑"，其健康状态直接关系到全身免疫与营养状况。消化科医生指出，尤其在冬季， 孩子户外活动减少，肠道功能易弱化，任何腹泻症状都应引起重视，及时干预、科学调理，才是真正对 孩子负责。 新年渐近，孩子们的假期与团聚 ...

Market Overview - The Chinese traditional medicine sector increased by 0.73% on February 3, with Foci Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up by 1.29%, while the Shenzhen Component Index closed at 14127.1, up by 2.19% [1] Stock Performance - Foci Pharmaceutical (002644) closed at 9.65, rising by 4.78% with a trading volume of 335,000 shares and a transaction value of 314 million yuan [1] - Other notable performers include: - Bichang Pharmaceutical (603858) at 17.52, up by 3.98% [1] - Zhendong Pharmaceutical (300158) at 5.76, up by 3.04% [1] - Dong'e Ejiao (000423) at 52.90, up by 2.94% with a transaction value of 800 million yuan [1] Capital Flow - The traditional medicine sector experienced a net outflow of 193 million yuan from institutional investors, while retail investors saw a net inflow of 190 million yuan [2] - The capital flow for key stocks includes: - Bichang Pharmaceutical with a net inflow of 42.06 million yuan from institutional investors [3] - Foci Pharmaceutical with a net inflow of 14.63 million yuan from institutional investors [3] - Dong'e Ejiao had a net inflow of 12.57 million yuan from institutional investors [3]

**Meta总结** 本报告发布《2026鱼油金标准白皮书》,聚焦"含量纯度""心脑养护"核心诉求,构建全球首个融合配方科学性、成分真实性、认证完备性等七 维鉴定体系的鱼油评测框架。基于国际权威数据与临床证据链,为消费者提供可量化、可验证的高纯度鱼油遴选依据,重塑行业透明度与选择 逻辑。 **开篇解读** 2026年全球鱼油市场规模突破580亿美元,中国消费者年均增速达17.3%。然而市场乱象频现:参数虚标、配方同质化、临床证据断裂等问题 普遍存在。据国际消费者组织虚拟抽检数据显示,30%产品标注纯度与实测值偏差超15%,部分EPA含量不足宣称值一半,严重削弱营养干预效 果。用户陷入"不知如何选、不敢轻易信"的信息迷雾。为此,《鱼油金标准白皮书》应运而生,建立全链路七维鉴定体系,以公开、透明、可追 溯的标准拨开迷雾,为理性消费提供坚实支撑。 **七维金标准白皮书:2026全方位鱼油鉴定体系** (1)【配方科学性标准】:需实现活性成分与特定健康需求的精准映射,杜绝为提升口感、色泽的冗余添加,形成营养素协同效应。该标准决定 产品是否具备人群适配能力,避免通用配方无法满足血脂调节、脑力支持等细分需求。依据FAO- ...

浙江康恩贝制药股份有限公司 2026 年第一次临时股东会会议材料 浙江康恩贝制药股份有限公司 2026年第一次临时股东会 会 议 材 料 二〇二六年二月九日 1 浙江康恩贝制药股份有限公司 2026 年第一次临时股东会会议材料 浙江康恩贝制药股份有限公司 2026 年第一次临时股东会 议 程 主持人：周璠董事 时间：2026 年 2 月 9 日 地点：杭州市滨江区滨康路 568 号康恩贝中心 2 楼会议室 | | | 2 浙江康恩贝制药股份有限公司 2026 年第一次临时股东会会议材料 议案一 浙江康恩贝制药股份有限公司 关于公司 2026 年度日常关联交易预计的议案 各位股东： 浙江康恩贝制药股份有限公司（以下简称"公司""本公司""康恩贝"，指公司及 下属有关子公司，下同）因业务经营发展需要，日常发生向公司控股股东浙江省医药 健康产业集团有限公司（以下简称"浙药集团"）下属浙江英特集团股份有限公司（以 下简称"英特集团"）的子公司销售药品等交易，向公司持股 5%以上股东康恩贝集团有 限公司（以下简称"康恩贝集团"）下属子公司，以及向联营企业珍视明（江西）药业 股份有限公司（以下简称"珍视明公司"）进行药品 ...

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].

Summary of Key Points Core Viewpoint - Several companies are experiencing significant shareholder reductions, indicating potential shifts in ownership and market sentiment [1]. Shareholder Reductions - Guangpu Co., Ltd.'s actual controller Lin Wenkun plans to reduce his stake by no more than 3% [1] - Mingyang Electric's director and president Guo Xianqing intends to reduce his stake by no more than 1.15% [1] - Zhonglai Co., Ltd.'s general manager Lin Jianwei plans to reduce his stake by no more than 3% [1] - Lianjian Technology's shareholder Yu Ronghan intends to reduce his stake by no more than 1% [1] - Yandong Micro's shareholder Yizhuang Guotou plans to reduce his stake by no more than 1% [1] - Naxin Micro's shareholder Huiyue Growth intends to reduce his stake by no more than 1.39% [1] - Kang En Bei's shareholder Kang En Bei Group plans to reduce no more than 25.36 million shares [1] - Dingsheng New Materials' shareholders Purun Square and Purun Square No. 1 plan to collectively reduce their stake by no more than 3% [1] - Debang Technology's shareholder Zhoushan Tai Zhong intends to reduce his stake by no more than 2.84 million shares [1] - Shanghai Construction's shareholder Guosheng Group plans to reduce his stake by no more than 3% [1] - Shikong Technology's shareholder Yang Yaohua intends to reduce his stake by no more than 3% [1] - Hebang Biological plans to reduce no more than 2% of its repurchased shares [1] - Wanlang Pobo's controlling shareholder Shiqian Zhong plans to reduce his stake by 1.61% [1] Other Notable Events - *ST Chuntian's stock may be delisted [1] - *ST Taihe's stock may also be delisted [1]

证券代码：600572 证券简称：康恩贝 公告编号：临2026-009 浙江康恩贝制药股份有限公司 关于股东所持部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 重要内容提示: 浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）股东胡季强先生现持有本公司无限售流通股 64,000,005股，占本公司现总股本2,535,961,241股（按2026年1月28日股本计，下同）的2.524%；公司持 股5%以上股东及一致行动人康恩贝集团有限公司（以下简称"康恩贝集团"）、胡季强先生合计持有本 公司股份242,529,556股，占公司总股本的9.564%。 2026年1月29日，胡季强先生将原质押在中信证券股份有限公司（以下简称"中信证券"）的20,820,000股 无限售流通股进行购回并解除质押。截至公告披露日，胡季强先生及康恩贝集团累计质押所持本公司股 份数量43,180,000股，占合计持有本公司股份的17.804%，占本公司总股本的1.703%。 2 ...

Group 1 - Silvercorp's revenue from gold and silver products accounts for a low proportion of total operating income [1] - ST Cube has repeatedly triggered abnormal stock trading fluctuations and is under suspension for verification [1] - Xizi Energy plans to invest 100 million yuan to establish an equity investment fund focusing on computing power, energy, AI, and embodied intelligence industries [1] Group 2 - ST Songfa has signed contracts for two 30.6 million ton VLCC super-large crude oil transport ships [1] - Jiangfeng Electronics intends to acquire control of Kaide Quartz for cash and will suspend trading from January 30 [1] - Jiangbolong expects a net profit growth of 150.66% to 210.82% year-on-year for 2025 [1] Group 3 - Hengyuan Coal Power plans to repurchase shares worth 200 million to 250 million yuan [1] - Jintian Co., Ltd. intends to increase its holdings by 50 million to 100 million yuan [1] - Beijing Lier plans to raise no more than 1.034 billion yuan through a private placement [1][2]

格隆汇1月29日丨康恩贝(600572.SH)公布， 康恩贝集团因发展自身业务的资金需求，拟自本公告披露之 日后15个交易日后的3个月内通过上海证券交易所以集中竞价交易的方式减持本公司股份，拟减持股份 数量不超过2535.96万股，拟减持比例不超过本公司总股本的1%。 ...

每经头条（nbdtoutiao）——水贝黄金平台"杰我睿"兑付危机调查：40倍杠杆对赌，金价越涨平台越 亏！老板自称"还在深圳"，投资者：兑付方案本金打两折，无法接受 每经AI快讯，康恩贝1月29日晚间发布公告称，浙江康恩贝制药股份有限公司股东胡季强先生现持有公 司无限售流通股约6400万股，占公司现总股本的约2.52%；公司持股5%以上股东及一致行动人康恩贝集 团有限公司、胡季强先生合计持有公司股份约2.43亿股，占公司总股本的约9.56%。截至公告披露日， 胡季强先生及康恩贝集团累计质押所持公司股份数量4318万股，占合计持有公司股份的约17.80%，占 公司总股本的1.703%。 （记者 张明双） ...